Loading
A phase 1/2 trial of AVZO-1418 in biliary tract cancer, bladder & urothelial cancer and nasopharyngeal carcinoma, run by Avenzo Therapeutics, Inc., now recruiting.
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) is a phase 1/2 interventional study registered as NCT07038343 by Avenzo Therapeutics, Inc., with 480 participants planned, started 2025-06-04 and due to reach its primary completion in 2030-06. Interventions recorded: AVZO-1418, Combination Agent 1 and Combination Agent 2.
Shares Avenzo Therapeutics, Bladder & urothelial cancer and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer and the tag pipeline.
Shares Avenzo Therapeutics and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.